Merlin, the NF2 Gene Product

Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B et al (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363:515–521

Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K et al (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791–800

Gusella JF, Ramesh V, MacCollin M, Jacoby LB (1999) Merlin: the neurofibromatosis 2 tumor suppressor. Biochim Biophys Acta 1423:M29–M36

Sughrue MI, Yeung AH, Rutkowski MJ, Cheung SW, Parsa AT (2011) Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics. J Neurosurg 114:359–366

Ammoun S, Hanemann CO (2011) Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol 7:3992–3999

Zhou L, Hanemann CO (2012) Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett 586:1403–1408

Hanemann CO (2008) Magic but treatable? Tumours due to loss of Merlin. Brain 131:606–615

Laulajainen M, Melikova M, Muranen T, Carpen O, Gronholm M (2012) Dictinct overlapping sequences at the carboxy-terminus of merlin regulate its tumor suppressor and morphogenic activity. J Cell Mol Med 16:2161–2175

Carroll SL (2012) Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol 123:321–348

Alfthan K, Heiska L, Grönholm M, Renkema GH, Carpén O (2004) Cyclic AMP-demendent protein kinase phosphorylates merlin at serine 518 independently of p21 activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem 279:18559–18566

McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T (1997) The NF2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev 11:1253–1265

Hanemann CO, Evans DG (2006) News on the genetics, epidemiology, medical care and translational research of Schwannomas. J Neurol 253:1533–1541

Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A, Thomas G (2000) Conditional biallelic NF2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 14:1617–1630

Lutchman M, Rouleau GA (1995) The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res 55:2270–2274

Tikoo A, Varga M, Ramesh V, Gusella J, Maruta H (1994) An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 269:23387–23390

Scoles DR (2008) The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta 1785:32–54

Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P (2001) The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15:968–980

Okada T, Lopez-Lago M, Giancotti FG (2005) Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol 171:361–371

Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI (2003) NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 17:1090–1100

Li W, Cooper J, Karajannis MA, Giancotti FG (2012) Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep 13:204–215

Kim H, Kwak NJ, Lee JY, Choi BH, Lim Y, Ko YJ, Kim YH, Huh PW, Lee KH, Rha HK, Wang YP (2004) Merlin neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 279:7812–7818

Fernandez-Valle C, Tang Y, Ricard J, Rodenas-Ruano A, Taylor A, Hackler E, Biggerstaff J, Iacovelli J (2002) Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 31:354–362

Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P (2007) Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 67:520–527

Fraenzer JT, Pan H, Minimo L Jr, Smith GM, Knauer D, Hung G (2003) Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 23:1493–1500

Okada M, Wang Y, Jang SW, Tang X, Neri LM, Ye K (2009) Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. Cancer Res 69:4043–4051

Bosco EE, Nakai Y, Hennigan RF, Ratner N, Zheng Y (2010) NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene 29:2540–2549

Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA, Hanemann CO (2011) Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-Catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia 13:1101–1112

Lau YKI, Murray LB, Houshmandi SS, Nu Y, Gutmann DH, Yu Q (2008) Merlin is a potent inhibitor of glioma growth. Cancer Res 68:5733–5742

Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841–846

Jacoby LB, MacCollin M, Barone R, Ramesh V, Gusella JF (1996) Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosom Cancer 17:45–55

Irving RM, Harada T, Moffat DA, Hardy DG, Whittaker JL, Xuereb JH, Maher ER (1997) Somatic neurofibromatosis type 2 gene mutations and growth characteristics in vestibular schwannoma. Am J Otol 18:754–760

Antinheimo J, Sallinen SL, Sallinen P, Haapasalo H, Helin H, Horelli-Kuitunen N, Wessman M, Sainio M, Jääskeläinen J, Carpén O (2000) Genetic aberrations in sporadic and neurofibromatosis 2 (NF2)-associated Schwannomas studied by comparative genomic hybridization (CGH). Acta Neurochir 142:1099–1105

Ahronowitz I, Xin W, Kiely R, Sims K, MacCollin M, Nunes FP (2007) Mutational spectrum of NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat 28:1–12

Welling DB, Akhmametyeva EM, Daniels RL, Lasak JM, Zhu L, Miles-Markley BA, Chang LS (2000) Analysis of the human neurofibromatosis type 2 gene promoter and its expression. Otolaryngology 123:413–418

Gutmann DH, Geist RT, Xu H, Kim JS, Saporito-Irwin S (1998) Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet 7:335–345

Fong B, Barkhoudarian G, Pezeshkian P, Parsa AT, Gopen Q, Yang I (2011) The molecular biology and novel treatments of vestibular schwannomas. J Neurosurg 115:906–914

Scheithauer BW, Louis DN, Hunter S, Woodruff JM, Antonescu CR (2007) Tumours of the cranial and paraspinal nerves. Schwannoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, Lyon, pp 152–155

Ghosh A, Talwar OP, Pradhan SV (2010) Tumour and tumour-like conditions of peripheral nerve origin: ten years’ experience. Kathmandu Univ Med J 29:97–101

Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER (1993) Molecular genetic analysis of the mechanism of tumorigenesis in acoustic neuroma. Arch Otolaryngol Head Neck Surg 119:1222–1228

Hitotsumatsu T, Iwaki T, Kitamoto T, Mizoguchi M, Suzuki SO, Hamada Y, Fukui M, Tateishi J (1997) Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. Acta Neuropathol 93:225–232

Lee DJ, Maseyesva B, Westra W, Long D, Niparko JK, Califano J (2006) Microsatellite analysis of recurrent vestibular Schwannoma (acoustic neuroma) following stereotactic radiosurgery. Otol Neurotol 27:213–219

Pećina-Šlaus N, Zeljko M, Pećina HI, Nikuševa Martić T, Bačić N, Tomas D, Hrašćan R (2012) Frequency of loss of heterozygosity of the NF2 gene in schwannomas from Croatian patients. Croat Med J 53:321–327

Bian LG, Sun QF, Tirakotai W, Zhao WG, Shen JK, Luo QZ, Bertalanffy H (2005) Loss of heterozygosity on chromosome 22 in sporadic schwannoma and its relation to the proliferation of tumor cells. Chin Med J (Engl) 118:1517–1524

Hadfield KD, Smith MJ, Urquhart JE, Wallace AJ, Bowers NL, King AT, Rutherford SA, Trump D, Newman WG, Evans DG (2010) Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 29:6216–6221

Mantripragada KK, Buckley PG, Benetkiewicz M, De Bustos C, Hirvela C, Jarbo C, Bruder CE, Wensman H, Mathiesen T, Nyberg G, Papi L, Collins VP, Ichimura K, Evans G, Dumanski JP (2003) High-resolution profiling of an 11 Mb segment of human chromosome 22 in sporadic schwannoma using array-CGH. Int J Oncol 22:615–622

Warren C, James LA, Ramsden RT, Wallace A, Baser ME, Varley JM, Evans DG (2003) Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridization. J Med Genet 40:802–806

Koutsimpelas D, Felmeden U, Mann WJ, Brieger J (2011) Analysis of cytogenetic aberrations in sporadic vestibular schwannoma by comparative genomic hybridization. J Neurooncol 103:437–443

Aarhus M, Bruland O, Sætran HA, Mork SJ, Lund-Johansen M, Knappskog PM (2010) Global gene expression profiling and tissue microarray reveal novel candidate genes and down-regulation of the tumor suppressor gene CAV1 in sporadic vestibular schwannomas. Neurosurgery 67:998–1019

Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T (1999) Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 59:5995–5998

Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Lekane dit Deprez R, Zwarthoff E (2001) NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 194:367–372

Fuller CE, Perry A (2005) Molecular diagnostics in central nervous system tumors. Adv Anat Pathol 12:180–194

Claus EB, Bondy ML, Wiemels JL, Wrensch M, Black PM (2005) Epidemiology of intracranial meningioma. Neurosurgery 57:1088–1094

Riemenschneider MJ, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 5:1045–1054

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109

Lee JY, Finkelstein S, Hamilton RL, Rekha R, King JT Jr, Omalu B (2004) Loss of heterozygosity analysis of benign, atypical, and anaplastic meningiomas. Neurosurgery 55:1163–1173

Ragel BT, Jensen RL (2005) Molecular genetics of meningiomas. Neurosurg Focus 119:E9

Barnholtz-Sloan JS, Kruchko C (2007) Meningiomas: causes and risk factors. Neurosurg Focus 23:E2

Pećina-Šlaus N, Nikuševa Martić T, Deak AJ, Zeljko M, Hrašćan R (2010) Genetic and protein changes of E-cadherin in meningiomas. J Cancer Res Clin Oncol 136:695–702

Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P (2007) Germline mutation of INI1/SMARCB1 in familial Schwannomatosis. Am J Hum Genet 80:805–810

Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M (2013) Update from the 2011 International Schwannomatosis Workshop: from genetics to diagnostic criteria. Am J Med Genet 161:405–416